Rivaroxaban CAS 366789-02-8 Maʻemaʻe >99.5% (HPLC) Factory API Kona Kiʻekiʻe
Mea Hana Mea Hana Rivaroxaban Nā Kūwaena Pili:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl)morpholin-3-hoʻokahi CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Inoa Kimia | Rivaroxaban |
Nā huaʻōlelo like | (S)-Rivaroxaban;(S)-5-Chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)-oxazolidin-5-yl)methyl)thiophene-2-carbox;BAY 59-7939 |
Helu CAS | 366789-02-8 |
Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā tona |
ʻĀpana Molekala | C19H18ClN3O5S |
Kaumaha Molecular | 435.88 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Pauda keʻokeʻo a ʻaneʻane keʻokeʻo |
ʻIkepili A | Hoʻopili ka infrared absorption o Rivaroxaban i nā kūlana kuhikuhi |
ʻIkepili B | ʻO ka manawa paʻa o ka piko nui o ka hāpana hāpana e pili ana i ka hopena kūpono o ka ʻōnaehana, e like me ka loaʻa ʻana i ka maʻemaʻe enantiomeric. |
Maʻemaʻe Enantiomeric | RVX RC01: ≤0.15% |
Māmā (KF) | ≤0.50% |
Lehu Sulphated | ≤0.10% |
Metala Kaumaha | ≤20ppm |
Acetic Acid | ≤5000ppm |
Nā mea pili (HPLC) | |
RVX RC02 | ≤0.15% |
RVX RC03 | ≤0.15% |
RVX RC04 | ≤0.15% |
RVX RC05 | ≤0.15% |
RVX RC06 | ≤0.15% |
RVX RC07 | ≤0.15% |
RVX RC08 | ≤0.15% |
ʻO nā mea haumia ʻē aʻe | ≤0.10% |
Huina paumaele | <0.50% |
Nā mea hoʻoheheʻe koena (GC) | |
Ethanol | ≤5000ppm |
Toluene | ≤890ppm |
Triethylamine | ≤320ppm |
Maʻemaʻe / Kaʻina Hanana | >99.5% (HPLC) (ma ke kumu anhydrous) |
Kūlana hoʻāʻo | ʻOihana Kūlana |
Hoʻohana | API;Laau Antithrombotic;FXa Kaohi |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.
Rivaroxaban(CAS:366789-02-8) (Xarelto, Bayer) he anticoagulant waha.ʻO ia ka mea hoʻopaneʻe Xa mea hoʻoheheʻe waha.Hōʻike ʻia ʻo Rivaroxaban no ka 'hana ʻana i ka thrombosis vein hohonu a me ka embolism pulmonary, a me ka pale ʻana i ka thrombosis hohonu hohonu a me ka embolism pulmonary i nā pākeke.No ka mālama mua ʻana i ka embolism pulmonary acute, ʻo ka rivaroxaban i ʻōlelo ʻia he 15 mg ʻelua i kēlā me kēia lā no nā lā 21 mua a ukali ʻia e 20 mg hoʻokahi i kēlā me kēia lā no ka mālama mau ʻana a me ka pale ʻana i ka thromboembolism venous hou.Non-Valvular Atrial Fibrillation (NVAF) e pale aku i ka hahau a me ka systemic embolism.ʻO ka mālama ʻana i ka VTE a me ka pale ʻana i ka VTE hou [no ka thrombosis vein hohonu (DVT) a me ka pulmonary embolism (PE)].Kāohi ʻana i nā hanana thromboembolic venous (VTE) ma ke kāʻei pani pani ʻana o ka ʻūhā a i ʻole ke kuli (THR, TKR).